For the year ending 2025-12-31, TXG had $129,899K increase in cash & cash equivalents over the period. $130,115K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -43,544 |
| Stock-based compensation expense | 109,118 |
| Depreciation and amortization | 36,199 |
| Asset and lease impairment charges | 814 |
| Rou assets impairment due to restructuring | 1,253 |
| Amortization of right-of-use assets | 7,617 |
| Fair value adjustments on contingent consideration | -1,407 |
| Realized loss on marketable securities | 0 |
| Other | -1,753 |
| Accounts receivable | -41,314 |
| Other receivables | 34,874 |
| Inventory | -27,953 |
| Prepaid expenses and other current assets | 2,343 |
| Other noncurrent assets | -689 |
| Accounts payable | -2,126 |
| Accrued compensation and other related benefits | 7,647 |
| Deferred revenue | 746 |
| Accrued expenses and other current liabilities | -5,153 |
| Operating lease liability | -10,310 |
| Other noncurrent liabilities | 1,396 |
| Net cash provided by (used in) operating activities | 136,050 |
| Proceeds from maturities of marketable securities | 125,200 |
| Proceeds from sales of marketable securities | 0 |
| Purchase of marketable securities | 123,435 |
| Asset acquisition, net | 9,268 |
| Purchases of property and equipment | 5,935 |
| Purchase of intangible assets | 0 |
| Net cash (used in) provided by investing activities | -13,438 |
| Issuance of common stock from exercise of stock options and employee stock purchase plan purchases | 6,803 |
| Payments on technology license financing arrangement | 0 |
| Net cash provided by financing activities | 6,803 |
| Effect of exchange rate changes on cash and cash equivalents | 484 |
| Net increase (decrease) in cash and cash equivalents | 129,899 |
| Cash and cash equivalents at beginning of period | 344,067 |
| Cash and cash equivalents at end of period | 473,966 |
10x Genomics, Inc. (TXG)
10x Genomics, Inc. (TXG)